FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1

Oncologist

Volumn 21, Issue 5, 2016, Pages 643-650

  Sul, Joohee ^a   Blumenthal, Gideon M ^a   Jiang, Xiaoping ^a   He, Kun ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Lung cancer; Pembrolizumab; Programmed death ligand 1; U.S. food and drug administration

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER STAGING; COLITIS; COUGHING; DECREASED APPETITE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CLINICAL TRIAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84966341112     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0498     Document Type: Article

References (12)

1. SEER Stat Fact Sheets: Lung and Bronchus Cancer. Available at http://seer.cancer.gov/statfacts/html/lungb.html. Accessed October 2015.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non small- cell lung cancer. N Engl JMed 2002;346:92–98.
3. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–1597.
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000;18: 2095–2103.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl JMed 2005;353:123–132.
6. Kazandjian D, Khozin S, Blumenthal G et al. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum based chemotherapy: A report from the US Food and Drug Administration. JAMA Oncol 2012;2:118–122.
7. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015–3029.
8. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–128.
9. Taal W, Oosterkamp HM, Walenkamp AM et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol 2014;15:943–953.
10. Blumenthal GM, Karuri SW, Zhang H et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;33:1008–1014.
11. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall- cell lung cancer. N Engl J Med 2015;373: 123–135.
12. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed 2015;372:2018–2028.